GlassScriptPhysician profile
Ana Everwine
NPI 1548628274
$1,459.67
in general payments reported to CMS, 2019-2025
23 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $394 · 2023: $548 · 2024: $178 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,066.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $354.84 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $223.44 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.33 | 2022-2025 | Jardiance, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $76.67 | 2022-2025 | Farxiga, Airsupra |
| Amgen INC. | $58.68 | 2023-2024 | Repatha, Otezla |
| Dynavax Technologies Corporation | $51.08 | 2023-2024 | Heplisav-B |
| Abbvie INC. | $50.05 | 2022-2025 | |
| Genentech USA, INC. | $46.33 | 2024 | Xolair |
| Bayer Healthcare Pharmaceuticals INC. | $34.62 | 2022 | |
| Astellas Pharma US INC | $34.32 | 2023 | Veozah |
| Glaxosmithkline, LLC. | $33.76 | 2025 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $32.25 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.43 | 2024-2025 | Xifaxan |
| Inspire Medical Systems, INC. | $26.64 | 2025 | Inspire |
| Alnylam Pharmaceuticals INC. | $26.43 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recor Medical INC | $24.55 | 2024 | Paradise Renal Denervation System |
| Pfizer INC. | $23.01 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.41 | 2025 | Trintellix |
| Halozyme INC | $20.00 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.36 | 2022 | |
| Dexcom, INC. | $18.49 | 2023 | Dexcom G6 Transmitter |
| Ironshore Pharmaceuticals INC. | $18.07 | 2023 | Jornay Pm |
| Lilly USA, LLC | $14.91 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Everwine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.